We’re Here to Help
Comprehensive genomic profiling (CGP) — also known as biomarker testing or tumor profiling — is a method of cancer testing that can find the mutations in your cancer’s DNA that may be causing your cancer to grow. The mutations in your cancer’s DNA may help your doctor identify a targeted therapy, immunotherapy, or clinical trial that is right for you. The resources below can help you navigate through the Foundation Medicine testing process.
For general information about CGP testing, available treatment options, and patient videos please visit StartWithStepOne.com.
FoundationOne CDx is an FDA-approved test for all solid tumor cancers performed on a tissue biopsy. It uses CGP to search 324 genes for cancer-relevant mutations in the DNA of your tumor to help identify targeted therapy, immunotherapy, and clinical trial options that may be right for you.
FoundationOne Liquid CDx is also an FDA-approved test for all solid tumors that analyzes over 300 genes from just a simple blood draw, called a liquid biopsy. FoundationOne Liquid CDx can help identify targeted therapy, immunotherapy, or clinical trial options that may be right for you.
FoundationOne Heme is a laboratory developed test for blood cancers like leukemia and lymphoma, and for sarcomas, that tests over 400 genes and biomarkers to identify targeted therapy, immunotherapy, or clinical trial options that may be right for you. The test can be performed on blood, bone marrow, or a tissue biopsy.
What Do the Results Mean?
When testing is complete, a report will be sent to your doctor. You can also request a copy of your report by contacting us. Ask your doctor about your Foundation Medicine testing options so they can help guide treatment decisions for you.
After we test your tumor tissue, blood, or bone marrow sample for gene mutations, we will list any mutations found in the report.
We also provide information about additional biomarkers that may be associated with immunotherapy response.
Making Testing Accessible
Foundation Medicine is committed to providing patients with resources and support throughout the testing process with the help of the FoundationAccess™ program. After your doctor orders a Foundation Medicine test and we receive your sample, we will contact you by phone, or mail you materials, to share important information about what you can expect as your test moves forward.
Some commercial health plans such as Cigna and many BlueCross BlueShield plans offer coverage for Foundation Medicine testing services.1 Medicare covers FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme for qualifying patients.2 FoundationOne CDx is also covered by TRICARE for qualifying patients. FoundationOne Heme has limited commercial health plan coverage at this time.
Financial assistance is available for qualifying patients who have out-of-pocket costs associated with Foundation Medicine testing.* Financial assistance is based on need and can be applied for at any time before during or after testing. Payment plans may also be available based on your financial situation.
*Foundation Medicine's Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.
For many patients with advanced solid tumors, FoundationOne CDx and FoundationOne Liquid CDx are covered by Medicare.
If you are an Original Medicare beneficiary and you meet the following criteria, Foundation Medicine expects that you will have no out-of-pocket costs for FoundationOne CDx or FoundationOne Liquid CDx solid tumor testing:
You have either recurrent, relapsed, refractory, metastatic, or advanced (stages III or IV) cancer;
This is your first time having a FoundationOne CDx or FoundationOne Liquid CDx test for this cancer diagnosis OR you had a FoundationOne CDx or FoundationOne Liquid CDx test before, but this is a different type of cancer—a “new primary” cancer diagnosis;
You have decided to seek further cancer treatment such as therapeutic chemotherapy; and
Your testing is ordered by a treating physician.
Note: If you are an Original Medicare beneficiary, you may need to sign an Advance Beneficiary Notice (ABN) prior to the test order. Your physician will determine if an ABN is required.
If you are an Original Medicare beneficiary and you meet the following criteria, Foundation Medicine expects that you will have no out-of-pocket expenses for your FoundationOne Heme testing:
You have been diagnosed with refractory/metastatic acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN) or you have a suspected myeloid malignancy with an undefined cytopenia for greater than 4 months, and other possible causes have been reasonably excluded, AND
You have not previously received or are not currently receiving NGS testing on the specimen for which the test is currently being ordered, AND
You have not been tested with the same test for the same genetic content
Note: If you are an Original Medicare customer, you may need to sign an Advance Beneficiary Notice (ABN) prior to the test order. Your physician will determine if an ABN is required.
Foundation Medicine will work directly with your insurance company to try to obtain coverage.
Depending on the terms of your insurance plan, you may have financial responsibility for co-pay, co-insurance, or deductible as directed by your plan.
If your insurance company denies coverage, with your consent, we will work on your behalf to attempt to obtain coverage and will work with you and your doctor in pursuing appeals to minimize the financial burden. If you are eligible for financial assistance, this is applied to your out-of-pocket cost.
Note: If you have private/commercial insurance, a prior authorization form may be required in some cases.
Answers to Common Questions
Foundation Medicine test results offer three possible options for you and your doctor to consider in your treatment:
FDA-approved therapies: We identify approved targeted therapies or immunotherapies that may help you based on the mutations and biomarkers found in your cancer. These therapies may have been approved for your cancer type or they may have been approved in other cancer types.
Rule out therapies: We look at hundreds of important genes to help your doctor know which medicines may not work for you.
Clinical trials: We match your results with medicines that are currently in development through clinical trials. Talk to your doctor about which clinical trial options may be available and if you might qualify.
Even a report with no actionable alterations can provide important information to your doctor that can help inform your treatment plan, rule out therapies that may not work for you, or confirm your current course of care.
Foundation Medicine accepts all insurance plans; however, we are currently not in-network providers with all insurance plans. If you are uninsured, or if you have insurance and cannot afford the applicable out-of-pocket cost, you have options. You can fill out a financial assistance application to help determine upfront what your maximum out-of-pocket expense might be. Payment plans may also be available. Please contact our Care Team for more detailed information.
In the event insurance does not cover testing, patients residing in the United States may be eligible to pay the adjusted rate of:
FoundationOne®CDx, FoundationOne®Liquid CDx, and FoundationOne®Heme: $3,500.00
PD-L1 (Immunohistochemistry): $125.00
Genomic testing looks at mutations in the tumor itself. Genetic testing looks at inherited mutations that are in all cells. Foundation Medicine testing is genomic testing, which looks at the mutations in the DNA of a tumor. These may have been inherited, or they may have been acquired over the course of a patient’s lifetime. We identify both kinds of mutations, but do not distinguish between the two. The mutations in the tumor are what may impact tumor growth, spread, and response to therapy.
FoundationOne CDx and FoundationOne Liquid CDx for solid tumor cancers are generally only used in more advanced stages. FoundationOne Heme for hematologic and soft tissue cancers can also be used at diagnosis, monitoring progression, and to guide overall clinical management. Talk to your doctor to see if our tests may be right for you.
From the time we receive your biopsy or blood sample, the typical turnaround time for a Foundation Medicine test is about two weeks. The report will be delivered to your physician.
Results can be shared with the patient per request via email, fax, or mail by contacting the Foundation Medicine Care Team at firstname.lastname@example.org or by calling +1 (888) 988-3639.
We’re Here to Help
If you didn’t find what you need or want to talk to someone further, our Care Team is on hand to help. Call +1 (888) 988-3639 or email email@example.com.
FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test please see the Technical Specifications at foundationmedicine.com/f1h.
1A select number of commercial payers have developed medical policy coverage for Foundation Medicine's FoundationOne CDx and FoundationOne Liquid CDx tests for commercially-insured patients. Foundation Medicine's other CGP test (FoundationOne Heme) has limited third party payer commercial coverage. In each case, coverage is pursuant to applicable payer medical policy and patient benefit plans.
2Medicare and Medicare Advantage members have coverage of FoundationOne CDx, FoundationOne Liquid CDx and FoundationOne Heme in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria
Important Safety Information
For prescription use only. FoundationOne CDx is a qualitative genomic sequencing test for advanced cancer patients with solid tumors and analyzes 324 genes. It is intended to help doctors identify which patients may benefit from treatment with certain therapies or through clinical trials. Use of the test does not guarantee that a patient will be matched to a treatment or that all relevant genomic alterations will be detected. Some patients may require a biopsy which poses certain risks. For the full product labeling, including indications for use and risk information, visit StartWithStepOne.com.
FoundationOne Liquid CDx
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.